Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo

Repaglinide (RPG), a rapid-acting meglitinide analog, is an oral hypoglycemic agent for patients with type 2 diabetes mellitus. Quercetin (QCT) is a well-known antioxidant and antidiabetic flavonoid that has been used as an important ingredient in many functional foods and complementary medicines. T...

Full description

Bibliographic Details
Main Authors: Ji-Min Kim, Seong-Wook Seo, Dong-Gyun Han, Hwayoung Yun, In-Soo Yoon
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/6/782
id doaj-cc2e3ad667514e71be8700b70ce3a62d
record_format Article
spelling doaj-cc2e3ad667514e71be8700b70ce3a62d2021-06-01T00:53:15ZengMDPI AGPharmaceutics1999-49232021-05-011378278210.3390/pharmaceutics13060782Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In VivoJi-Min Kim0Seong-Wook Seo1Dong-Gyun Han2Hwayoung Yun3In-Soo Yoon4Department of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, KoreaDepartment of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, KoreaDepartment of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, KoreaDepartment of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, KoreaDepartment of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, KoreaRepaglinide (RPG), a rapid-acting meglitinide analog, is an oral hypoglycemic agent for patients with type 2 diabetes mellitus. Quercetin (QCT) is a well-known antioxidant and antidiabetic flavonoid that has been used as an important ingredient in many functional foods and complementary medicines. This study aimed to comprehensively investigate the effects of QCT on the metabolism of RPG and its underlying mechanisms. The mean (range) IC<sub>50</sub> of QCT on the microsomal metabolism of RPG was estimated to be 16.7 (13.0–18.6) μM in the rat liver microsome (RLM) and 3.0 (1.53–5.44) μM in the human liver microsome (HLM). The type of inhibition exhibited by QCT on RPG metabolism was determined to be a mixed inhibition with a K<sub>i</sub> of 72.0 μM in RLM and 24.2 μM in HLM as obtained through relevant graphical and enzyme inhibition model-based analyses. Furthermore, the area under the plasma concentration versus time curve (AUC) and peak plasma concentration (C<sub>max</sub>) of RPG administered intravenously and orally in rats were significantly increased by 1.83- and 1.88-fold, respectively, after concurrent administration with QCT. As the protein binding and blood distribution of RPG were observed to be unaltered by QCT, it is plausible that the hepatic first-pass and systemic metabolism of RPG could have been inhibited by QCT, resulting in the increased systemic exposure (AUC and C<sub>max</sub>) of RPG. These results suggest that there is a possibility that clinically significant pharmacokinetic interactions between QCT and RPG could occur, depending on the extent and duration of QCT intake from foods and dietary supplements.https://www.mdpi.com/1999-4923/13/6/782drug-phytochemical interactionhepatic metabolismmixed inhibitionquercetinrepaglinide
collection DOAJ
language English
format Article
sources DOAJ
author Ji-Min Kim
Seong-Wook Seo
Dong-Gyun Han
Hwayoung Yun
In-Soo Yoon
spellingShingle Ji-Min Kim
Seong-Wook Seo
Dong-Gyun Han
Hwayoung Yun
In-Soo Yoon
Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo
Pharmaceutics
drug-phytochemical interaction
hepatic metabolism
mixed inhibition
quercetin
repaglinide
author_facet Ji-Min Kim
Seong-Wook Seo
Dong-Gyun Han
Hwayoung Yun
In-Soo Yoon
author_sort Ji-Min Kim
title Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo
title_short Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo
title_full Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo
title_fullStr Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo
title_full_unstemmed Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo
title_sort assessment of metabolic interaction between repaglinide and quercetin via mixed inhibition in the liver: in vitro and in vivo
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2021-05-01
description Repaglinide (RPG), a rapid-acting meglitinide analog, is an oral hypoglycemic agent for patients with type 2 diabetes mellitus. Quercetin (QCT) is a well-known antioxidant and antidiabetic flavonoid that has been used as an important ingredient in many functional foods and complementary medicines. This study aimed to comprehensively investigate the effects of QCT on the metabolism of RPG and its underlying mechanisms. The mean (range) IC<sub>50</sub> of QCT on the microsomal metabolism of RPG was estimated to be 16.7 (13.0–18.6) μM in the rat liver microsome (RLM) and 3.0 (1.53–5.44) μM in the human liver microsome (HLM). The type of inhibition exhibited by QCT on RPG metabolism was determined to be a mixed inhibition with a K<sub>i</sub> of 72.0 μM in RLM and 24.2 μM in HLM as obtained through relevant graphical and enzyme inhibition model-based analyses. Furthermore, the area under the plasma concentration versus time curve (AUC) and peak plasma concentration (C<sub>max</sub>) of RPG administered intravenously and orally in rats were significantly increased by 1.83- and 1.88-fold, respectively, after concurrent administration with QCT. As the protein binding and blood distribution of RPG were observed to be unaltered by QCT, it is plausible that the hepatic first-pass and systemic metabolism of RPG could have been inhibited by QCT, resulting in the increased systemic exposure (AUC and C<sub>max</sub>) of RPG. These results suggest that there is a possibility that clinically significant pharmacokinetic interactions between QCT and RPG could occur, depending on the extent and duration of QCT intake from foods and dietary supplements.
topic drug-phytochemical interaction
hepatic metabolism
mixed inhibition
quercetin
repaglinide
url https://www.mdpi.com/1999-4923/13/6/782
work_keys_str_mv AT jiminkim assessmentofmetabolicinteractionbetweenrepaglinideandquercetinviamixedinhibitionintheliverinvitroandinvivo
AT seongwookseo assessmentofmetabolicinteractionbetweenrepaglinideandquercetinviamixedinhibitionintheliverinvitroandinvivo
AT donggyunhan assessmentofmetabolicinteractionbetweenrepaglinideandquercetinviamixedinhibitionintheliverinvitroandinvivo
AT hwayoungyun assessmentofmetabolicinteractionbetweenrepaglinideandquercetinviamixedinhibitionintheliverinvitroandinvivo
AT insooyoon assessmentofmetabolicinteractionbetweenrepaglinideandquercetinviamixedinhibitionintheliverinvitroandinvivo
_version_ 1721413676984958976